NMS 1116354

Drug Profile

NMS 1116354

Alternative Names: NMS-1116354; NMS-354; PHA-767491

Latest Information Update: 05 Feb 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nerviano Medical Sciences
  • Class Antineoplastics; Piperidones; Pyrroles; Small molecules
  • Mechanism of Action CDC7 protein kinase inhibitors; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 05 Feb 2013 Discontinued - Phase-I for Solid tumours in France (PO)
  • 05 Feb 2013 Discontinued - Phase-I for Solid tumours in USA (PO)
  • 16 Nov 2010 Efficacy, adverse events and pharmacokinetics data from a phase I trial in Solid tumours presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top